|
PRESENTATION
|
|
Traditional targeted assays struggle to capture the full picture of per- and polyfluoroalkyl substances (PFAS) in humans. This webinar explores a comprehensive non-targeted workflow using high-resolution mass spectrometry and FluoroMatch Suite software that overcomes this limitation. It will cover various acquisition methods with various Agilent instrumentation including the Revident, 6546, and 6560. Benchmarking against targeted methodologies, this non-targeted workflow both provides confident annotations and comprehensive analysis, allowing for the discovery of new or rarely screened PFAS. The workflow examines dried blood spots (DBS), whole blood, and urine from various populations and animal models. Furthermore, it examines biotransformation products of PFAS using mouse models, as well as gluconic acid conjugates as major transformation products of various PFAS precursors. The study successfully identified 4 previously unknown or rarely screened PFAS in DBS and whole blood from various populations in different parts of the globe, including a class of emerging concern called perfluoroalkyl ether carboxylic acids (PFECA). This research has significant implications for public health. By revealing the full spectrum of PFAS exposure, it can inform targeted widescale monitoring, research, and policies that lead to improved monitoring and regulation of these widespread contaminants.
|
